No role for CXCL12-G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia

Leukemia. 2008 Mar;22(3):669-71. doi: 10.1038/sj.leu.2404938. Epub 2007 Sep 6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemokine CXCL12 / genetics*
  • Chemokine CXCL12 / physiology
  • Disease-Free Survival
  • Female
  • Genotype
  • Humans
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / genetics*
  • Leukemia, Myeloid / mortality
  • Leukemia, Myeloid / pathology
  • Male
  • Middle Aged
  • Neoplasm Proteins / genetics*
  • Neoplasm Proteins / physiology
  • Polymorphism, Single Nucleotide*
  • Proportional Hazards Models
  • Receptors, CXCR4 / physiology
  • Remission Induction
  • Sarcoma, Myeloid / drug therapy
  • Sarcoma, Myeloid / genetics*
  • Sarcoma, Myeloid / pathology
  • Survival Analysis

Substances

  • CXCL12 protein, human
  • CXCR4 protein, human
  • Chemokine CXCL12
  • Neoplasm Proteins
  • Receptors, CXCR4